Trial
|
Period
|
n
|
Hypofraction schedule
|
SIB
|
Mastectomy
|
Regional nodes
|
IMRT/ IGRT
|
Chemo-therapy
|
Outcome
|
---|
Hôpital Necker (*)[32]
|
1982-
|
230
|
5.75 Gy x 4 F/ 17
|
No
|
Yes
|
?
|
NS
|
Yes
|
=
|
1984
|
days
|
Royal Marsden Hospital[33]
|
1986-
|
1410
|
3 Gy x 13 F/ 5
|
No
|
No
|
Yes
|
NS
|
No
|
More local relapses
|
1998
|
weeks
|
Royal Marsden Hospital
| | |
3.3 Gy x 13 F/ 5
|
No
|
No
|
Yes
|
NS
|
No
|
=
|
weeks
|
Ontario[18]
|
1993-
|
1234
|
2.66 Gy x 16 F/ 3
|
No
|
No
|
No
|
NS
|
Yes
|
=
|
1996
|
weeks
|
UK Start A[19]
|
1998-
|
2236
|
3 Gy x 13 F/ 5
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
More local relapses
|
2002
|
weeks
|
UK Start A
| | |
3.2 Gy x 13 F/ 5
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
=
|
weeks
|
Lahore[34]
|
1998-
|
300
|
5.4 Gy x 5 F/ 1
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
=
|
2004
|
week
|
Lahore
| | |
3.5 Gy x 10 F/ 2
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
=
|
weeks
|
Lahore
| | |
2.66 Gy x 15 F/ 3
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
Control arm
|
weeks
|
UK Start B[20]
|
1999-
|
2215
|
2.67 Gy x 15 F/ 3
|
No
|
Yes
|
Yes
|
NS
|
Yes
|
=
|
2001
|
weeks
|
Egypt NCI[35]
|
2002-
|
30
|
2.66 Gy x 16 F/ 3
|
No
|
No
|
No
|
NS
|
No
|
Boost in conventional arm
|
2003
|
weeks
|
UK FAST[36]
|
2004-
|
915
|
5.7 Gy x 5 F/ 5
|
?
|
No
|
No
|
Yes
|
No
|
=
|
2007
|
weeks
|
UK FAST
| | |
6 Gy x 5 F/ 5
|
?
|
No
|
No
|
Yes
|
No
|
More breast toxicity
|
weeks
|
DBCG 2009 RT Hypo[37]
|
2009-
|
1500**
|
2.67 Gy x 15 F/ 3
|
No
|
No
|
No
|
Yes
|
Yes
|
On-going
|
weeks
|
UK IMPORT HIGH
|
2009-
|
840**
|
2.4 Gy [SIB 3.2 Gy]
|
Yes
|
No
|
?
|
Yes
|
?
|
On-going
|
x 15 F/
|
UK IMPORT HIGH
| | |
2.4 Gy [SIB 3.53 Gy]
|
Yes
|
No
|
?
|
Yes
|
?
| |
x 15 F/
|
UZ Brussel
|
2007-
|
122
|
2.8 Gy [SIB 3.4 Gy]
|
Yes
|
Yes
|
Yes
|
Yes
|
Yes
|
Closed for inclusion; FU on-going
|
[this study]
|
x 15 F/ 3 weeks
|
- (*) Partial report; full study 1982–1989, n = 525 patients. (**) Planned accrual.
- NS: not stated. =: outcome comparable with control arm. SIB: simultaneous integrated boost. FU: follow-up.